EA019833B1 - Вещества, связывающие ядерные рецепторы - Google Patents

Info

Publication number

EA019833B1

EA019833B1 EA200970707A EA200970707A EA019833B1 EA 019833 B1 EA019833 B1 EA 019833B1 EA 200970707 A EA200970707 A EA 200970707A EA 200970707 A EA200970707 A EA 200970707A EA 019833 B1 EA019833 B1 EA 019833B1

Authority

EA

Eurasian Patent Office

Prior art keywords

hydroxyphenyl

hydroxy

compound

another embodiment

present

Prior art date

2007-01-22

Links

• Espacenet
• Global Dossier
• Discuss

• 108020005497 Nuclear hormone receptor Proteins 0.000 title claims abstract description 39
• 102000006255 nuclear receptors Human genes 0.000 title claims abstract description 38
• 108020004017 nuclear receptors Proteins 0.000 title claims abstract description 38
• 239000011230 binding agent Substances 0.000 title claims abstract description 8
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 85
• 238000011282 treatment Methods 0.000 claims abstract description 74
• 201000010099 disease Diseases 0.000 claims abstract description 54
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 51
• 208000001132 Osteoporosis Diseases 0.000 claims abstract description 36
• 208000035475 disorder Diseases 0.000 claims abstract description 31
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 29
• 206010060862 Prostate cancer Diseases 0.000 claims abstract description 28
• 210000002307 prostate Anatomy 0.000 claims abstract description 24
• 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 19
• 230000002265 prevention Effects 0.000 claims abstract description 13
• 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
• 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
• 150000001875 compounds Chemical class 0.000 claims description 322
• 230000000694 effects Effects 0.000 claims description 99
• 150000003839 salts Chemical class 0.000 claims description 78
• -1 cyano, phenyl Chemical group 0.000 claims description 59
• 210000001519 tissue Anatomy 0.000 claims description 57
• 210000000988 bone and bone Anatomy 0.000 claims description 42
• 230000006378 damage Effects 0.000 claims description 42
• 229910052739 hydrogen Inorganic materials 0.000 claims description 33
• 239000008194 pharmaceutical composition Substances 0.000 claims description 33
• 239000001257 hydrogen Substances 0.000 claims description 30
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
• 206010061218 Inflammation Diseases 0.000 claims description 26
• 201000011510 cancer Diseases 0.000 claims description 26
• 230000004054 inflammatory process Effects 0.000 claims description 26
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 24
• 201000001320 Atherosclerosis Diseases 0.000 claims description 24
• 125000004432 carbon atom Chemical group C* 0.000 claims description 21
• 150000002632 lipids Chemical class 0.000 claims description 20
• 125000000217 alkyl group Chemical group 0.000 claims description 19
• 206010020772 Hypertension Diseases 0.000 claims description 18
• 229910052736 halogen Inorganic materials 0.000 claims description 18
• 150000002367 halogens Chemical class 0.000 claims description 18
• 150000002431 hydrogen Chemical class 0.000 claims description 18
• 208000029078 coronary artery disease Diseases 0.000 claims description 14
• 239000003085 diluting agent Substances 0.000 claims description 14
• 208000024827 Alzheimer disease Diseases 0.000 claims description 13
• 208000010392 Bone Fractures Diseases 0.000 claims description 13
• 239000003795 chemical substances by application Substances 0.000 claims description 13
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
• 206010003246 arthritis Diseases 0.000 claims description 11
• 125000003118 aryl group Chemical group 0.000 claims description 11
• 230000009245 menopause Effects 0.000 claims description 11
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
• 208000006011 Stroke Diseases 0.000 claims description 10
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
• 230000004792 oxidative damage Effects 0.000 claims description 10
• 239000002243 precursor Substances 0.000 claims description 10
• 208000024891 symptom Diseases 0.000 claims description 9
• OOOIOILEQULOBV-UHFFFAOYSA-N 4-bromo-6-methoxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(OC)C=C2C(Br)=C1 OOOIOILEQULOBV-UHFFFAOYSA-N 0.000 claims description 8
• 210000000481 breast Anatomy 0.000 claims description 8
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
• BIUDJVBDYHJCCR-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(Br)=C1 BIUDJVBDYHJCCR-UHFFFAOYSA-N 0.000 claims description 7
• 102000019197 Superoxide Dismutase Human genes 0.000 claims description 7
• 108010012715 Superoxide dismutase Proteins 0.000 claims description 7
• 208000030533 eye disease Diseases 0.000 claims description 7
• 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
• 208000032839 leukemia Diseases 0.000 claims description 7
• 239000011707 mineral Substances 0.000 claims description 7
• 230000004770 neurodegeneration Effects 0.000 claims description 7
• 239000002245 particle Substances 0.000 claims description 7
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
• 208000010412 Glaucoma Diseases 0.000 claims description 6
• 208000029742 colonic neoplasm Diseases 0.000 claims description 6
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
• 125000001188 haloalkyl group Chemical group 0.000 claims description 6
• 206010020718 hyperplasia Diseases 0.000 claims description 6
• 208000002780 macular degeneration Diseases 0.000 claims description 6
• 229910052760 oxygen Inorganic materials 0.000 claims description 6
• DEDJPVYPSZIEAL-UHFFFAOYSA-N 4-ethenyl-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(C=C)=C1 DEDJPVYPSZIEAL-UHFFFAOYSA-N 0.000 claims description 5
• HKNUGPCAHQCTKA-UHFFFAOYSA-N 8-hydroxy-6-methoxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(O)C=C(OC)C=C2C=C1 HKNUGPCAHQCTKA-UHFFFAOYSA-N 0.000 claims description 5
• 201000004384 Alopecia Diseases 0.000 claims description 5
• 206010005003 Bladder cancer Diseases 0.000 claims description 5
• 206010009944 Colon cancer Diseases 0.000 claims description 5
• 206010019280 Heart failures Diseases 0.000 claims description 5
• 208000022873 Ocular disease Diseases 0.000 claims description 5
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
• 230000001413 cellular effect Effects 0.000 claims description 5
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
• 230000003902 lesion Effects 0.000 claims description 5
• 239000001301 oxygen Substances 0.000 claims description 5
• 230000008506 pathogenesis Effects 0.000 claims description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
• 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 5
• 208000017497 prostate disease Diseases 0.000 claims description 5
• 208000017520 skin disease Diseases 0.000 claims description 5
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
• 208000019553 vascular disease Diseases 0.000 claims description 5
• MEDJRANHIIJXIE-UHFFFAOYSA-N 4,5-dibromo-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C(Br)=C2C(Br)=C1 MEDJRANHIIJXIE-UHFFFAOYSA-N 0.000 claims description 4
• JHMDJCQHWGALEV-UHFFFAOYSA-N 4-bromo-2-(4-hydroxyphenyl)-6-methoxyisoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C2=O)C=1C(Br)=CN2C1=CC=C(O)C=C1 JHMDJCQHWGALEV-UHFFFAOYSA-N 0.000 claims description 4
• GLVQMSCCFOGRRG-UHFFFAOYSA-N 4-bromo-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C=C2C(Br)=C1 GLVQMSCCFOGRRG-UHFFFAOYSA-N 0.000 claims description 4
• IYKXSJBWAQMFEC-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-8-carbonitrile Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(C#N)C=C(O)C=C2C(Br)=C1 IYKXSJBWAQMFEC-UHFFFAOYSA-N 0.000 claims description 4
• MEUSXTGMSNLMBW-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-8-carboxylic acid Chemical compound O=C1C=2C(C(=O)O)=CC(O)=CC=2C(Br)=CN1C1=CC=C(O)C=C1 MEUSXTGMSNLMBW-UHFFFAOYSA-N 0.000 claims description 4
• VACHIUUKYZPGPP-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(Br)=C1 VACHIUUKYZPGPP-UHFFFAOYSA-N 0.000 claims description 4
• FSCSPCCXODGFCH-UHFFFAOYSA-N 4-bromo-6-methoxy-2-(4-methoxyphenyl)-1-oxoisoquinoline-8-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(C#N)C=C(OC)C=C2C(Br)=C1 FSCSPCCXODGFCH-UHFFFAOYSA-N 0.000 claims description 4
• IWXWZDBKLIOSJS-UHFFFAOYSA-N 5-bromo-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C(Br)=C2C=C1 IWXWZDBKLIOSJS-UHFFFAOYSA-N 0.000 claims description 4
• XRAULIOBQVWAHA-UHFFFAOYSA-N 5-bromo-8-hydroxy-2-(4-hydroxyphenyl)-6-methoxyisoquinolin-1-one Chemical compound BrC=1C(OC)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C=C1 XRAULIOBQVWAHA-UHFFFAOYSA-N 0.000 claims description 4
• LRLIGCRQCHORKS-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-4-carbonitrile Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(C#N)=C1 LRLIGCRQCHORKS-UHFFFAOYSA-N 0.000 claims description 4
• YECTYKMUECXIIC-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-4-phenylisoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(C=2C=CC=CC=2)=C1 YECTYKMUECXIIC-UHFFFAOYSA-N 0.000 claims description 4
• VXWNVOAOZHHSAJ-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)-1-oxoisoquinoline-8-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(C#N)C=C(OC)C=C2C=C1 VXWNVOAOZHHSAJ-UHFFFAOYSA-N 0.000 claims description 4
• UKTXTSFJQVTSDF-UHFFFAOYSA-N 8-hydroxy-2-(4-hydroxyphenyl)-6-methoxy-1-oxoisoquinoline-5-carbonitrile Chemical compound N#CC=1C(OC)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C=C1 UKTXTSFJQVTSDF-UHFFFAOYSA-N 0.000 claims description 4
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
• 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 4
• 206010014733 Endometrial cancer Diseases 0.000 claims description 4
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
• 208000033830 Hot Flashes Diseases 0.000 claims description 4
• 206010060800 Hot flush Diseases 0.000 claims description 4
• 208000018737 Parkinson disease Diseases 0.000 claims description 4
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
• 206010063493 Premature ageing Diseases 0.000 claims description 4
• 208000032038 Premature aging Diseases 0.000 claims description 4
• 206010054880 Vascular insufficiency Diseases 0.000 claims description 4
• 208000024963 hair loss Diseases 0.000 claims description 4
• 230000003676 hair loss Effects 0.000 claims description 4
• 201000001421 hyperglycemia Diseases 0.000 claims description 4
• 239000000543 intermediate Substances 0.000 claims description 4
• 208000028867 ischemia Diseases 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 230000002093 peripheral effect Effects 0.000 claims description 4
• 208000037803 restenosis Diseases 0.000 claims description 4
• 208000023577 vascular insufficiency disease Diseases 0.000 claims description 4
• RQUQUZXEFIIGJT-UNXLUWIOSA-N (e)-3-[6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinolin-4-yl]prop-2-enoic acid Chemical compound O=C1C2=CC=C(O)C=C2C(/C=C/C(=O)O)=CN1C1=CC=C(O)C=C1 RQUQUZXEFIIGJT-UNXLUWIOSA-N 0.000 claims description 3
• CYOPMEZSMPDHMG-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-6-hydroxy-4-iodoisoquinolin-1-one Chemical compound C=1C(O)=CC=C(C2=O)C=1C(I)=CN2C1=CC=C(O)C(F)=C1 CYOPMEZSMPDHMG-UHFFFAOYSA-N 0.000 claims description 3
• VQWVUJRCBBKKQM-UHFFFAOYSA-N 4,5-dibromo-2-(3,5-dibromo-4-hydroxyphenyl)-6-hydroxyisoquinolin-1-one Chemical compound BrC=1C(O)=CC=C(C2=O)C=1C(Br)=CN2C1=CC(Br)=C(O)C(Br)=C1 VQWVUJRCBBKKQM-UHFFFAOYSA-N 0.000 claims description 3
• RMCDCECZLOHHME-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-8-carboxamide Chemical compound O=C1C=2C(C(=N)O)=CC(O)=CC=2C(Br)=CN1C1=CC=C(O)C=C1 RMCDCECZLOHHME-UHFFFAOYSA-N 0.000 claims description 3
• KDIJFTYBJBYCJT-UHFFFAOYSA-N 4-bromo-8-ethenyl-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(C=C)C=C(O)C=C2C(Br)=C1 KDIJFTYBJBYCJT-UHFFFAOYSA-N 0.000 claims description 3
• DOIDLZJLHMHFHM-UHFFFAOYSA-N 4-chloro-6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-8-carbonitrile Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(C#N)C=C(O)C=C2C(Cl)=C1 DOIDLZJLHMHFHM-UHFFFAOYSA-N 0.000 claims description 3
• QAGWYKCFYYZWRQ-NSCUHMNNSA-N 6,8-dihydroxy-2-(4-hydroxyphenyl)-4-[(e)-prop-1-enyl]isoquinolin-1-one Chemical compound O=C1C2=C(O)C=C(O)C=C2C(/C=C/C)=CN1C1=CC=C(O)C=C1 QAGWYKCFYYZWRQ-NSCUHMNNSA-N 0.000 claims description 3
• SEVQUOTVBDFALI-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)-1-oxoisoquinoline-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(OC)C=C2C(C#N)=C1 SEVQUOTVBDFALI-UHFFFAOYSA-N 0.000 claims description 3
• 206010058314 Dysplasia Diseases 0.000 claims description 3
• 206010019799 Hepatitis viral Diseases 0.000 claims description 3
• 208000023105 Huntington disease Diseases 0.000 claims description 3
• 206010025323 Lymphomas Diseases 0.000 claims description 3
• 206010071019 Prostatic dysplasia Diseases 0.000 claims description 3
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
• 208000017442 Retinal disease Diseases 0.000 claims description 3
• HHUHTHMCYBGIEQ-UHFFFAOYSA-N [6-methoxy-2-(4-methoxyphenyl)-1-oxoisoquinolin-8-yl] trifluoromethanesulfonate Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(OS(=O)(=O)C(F)(F)F)C=C(OC)C=C2C=C1 HHUHTHMCYBGIEQ-UHFFFAOYSA-N 0.000 claims description 3
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
• 239000013256 coordination polymer Substances 0.000 claims description 3
• 230000006872 improvement Effects 0.000 claims description 3
• 201000006370 kidney failure Diseases 0.000 claims description 3
• 208000010125 myocardial infarction Diseases 0.000 claims description 3
• 201000001862 viral hepatitis Diseases 0.000 claims description 3
• TVOCNPSVVIIQRF-LZCJLJQNSA-N (e)-3-[6,8-dihydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinolin-4-yl]prop-2-enoic acid Chemical compound O=C1C2=C(O)C=C(O)C=C2C(/C=C/C(=O)O)=CN1C1=CC=C(O)C=C1 TVOCNPSVVIIQRF-LZCJLJQNSA-N 0.000 claims description 2
• KJAKOSACJWWFAE-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-6,8-dihydroxy-1-oxoisoquinoline-4-carbonitrile Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1C(C#N)=CN2C1=CC=C(O)C(F)=C1 KJAKOSACJWWFAE-UHFFFAOYSA-N 0.000 claims description 2
• YZBDHJCQDCMPRH-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-8-hydroxy-6-methoxyisoquinolin-1-one Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C(F)=C1 YZBDHJCQDCMPRH-UHFFFAOYSA-N 0.000 claims description 2
• MSSQOQPKGAMUSY-LEAFIULHSA-N 2-[1-[2-[(4r,6s)-8-chloro-6-(2,3-dimethoxyphenyl)-4,6-dihydropyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C=CC=C3[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC MSSQOQPKGAMUSY-LEAFIULHSA-N 0.000 claims description 2
• CODBZFJPKJDNDT-UHFFFAOYSA-N 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione Chemical compound CN(C)CCCC1=CN=C(C)C(NC=2N=C3C4=CC=C(C=C4NC(=S)CC3=CN=2)C(F)(F)F)=C1 CODBZFJPKJDNDT-UHFFFAOYSA-N 0.000 claims description 2
• TYWJUKOBNZCZNP-UHFFFAOYSA-N 4-bromo-2-(3-fluoro-4-hydroxyphenyl)-6,8-dihydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1C(Br)=CN2C1=CC=C(O)C(F)=C1 TYWJUKOBNZCZNP-UHFFFAOYSA-N 0.000 claims description 2
• CJNRHMOCAFYPNU-UHFFFAOYSA-N 4-bromo-2-(3-fluoro-4-hydroxyphenyl)-6-hydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC=C(C2=O)C=1C(Br)=CN2C1=CC=C(O)C(F)=C1 CJNRHMOCAFYPNU-UHFFFAOYSA-N 0.000 claims description 2
• QJLDXJQEOCNNNN-UHFFFAOYSA-N 4-bromo-8-hydroxy-2-(4-hydroxyphenyl)-6-methoxyisoquinolin-1-one Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1C(Br)=CN2C1=CC=C(O)C=C1 QJLDXJQEOCNNNN-UHFFFAOYSA-N 0.000 claims description 2
• AZVDUDPENBFRBD-UHFFFAOYSA-N 4-chloro-2-(3-fluoro-4-hydroxyphenyl)-6-hydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC=C(C2=O)C=1C(Cl)=CN2C1=CC=C(O)C(F)=C1 AZVDUDPENBFRBD-UHFFFAOYSA-N 0.000 claims description 2
• OBMYVDPMHJENSJ-UHFFFAOYSA-N 4-chloro-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C=C2C(Cl)=C1 OBMYVDPMHJENSJ-UHFFFAOYSA-N 0.000 claims description 2
• OPZIIRQRKPWJSM-UHFFFAOYSA-N 4-chloro-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(Cl)=C1 OPZIIRQRKPWJSM-UHFFFAOYSA-N 0.000 claims description 2
• CZBBISPIFFGFNF-UHFFFAOYSA-N 4-chloro-6-methoxy-2-(4-methoxyphenyl)-1-oxoisoquinoline-8-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(C#N)C=C(OC)C=C2C(Cl)=C1 CZBBISPIFFGFNF-UHFFFAOYSA-N 0.000 claims description 2
• UZCGSEMPWJYIKG-UHFFFAOYSA-N 4-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-6,8-dihydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1C(C=C)=CN2C1=CC=C(O)C(F)=C1 UZCGSEMPWJYIKG-UHFFFAOYSA-N 0.000 claims description 2
• PPTSOUXIGWOEEF-UHFFFAOYSA-N 4-ethenyl-6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-8-carbonitrile Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(C#N)C=C(O)C=C2C(C=C)=C1 PPTSOUXIGWOEEF-UHFFFAOYSA-N 0.000 claims description 2
• ICHQVQAPJAPFIA-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-8-carbonitrile Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(C#N)C=C(O)C=C2C=C1 ICHQVQAPJAPFIA-UHFFFAOYSA-N 0.000 claims description 2
• BVCSBABZBDLYNM-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-4-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1C(C1=CC(O)=CC=C1C1=O)=CN1C1=CC=C(O)C=C1 BVCSBABZBDLYNM-UHFFFAOYSA-N 0.000 claims description 2
• DWJWQCHKPAXAQA-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-4-iodoisoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(I)=C1 DWJWQCHKPAXAQA-UHFFFAOYSA-N 0.000 claims description 2
• NLICMTXFTAFGFM-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C=C1 NLICMTXFTAFGFM-UHFFFAOYSA-N 0.000 claims description 2
• LCHGFAHHVISDQP-UHFFFAOYSA-N 6-hydroxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(O)C=C2C=C1 LCHGFAHHVISDQP-UHFFFAOYSA-N 0.000 claims description 2
• GMVOYYCBEMQVIQ-UHFFFAOYSA-N 8-ethenyl-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(C=C)C=C(O)C=C2C=C1 GMVOYYCBEMQVIQ-UHFFFAOYSA-N 0.000 claims description 2
• XMQDHAVDMCJSCU-UHFFFAOYSA-N 8-hydroxy-2-(4-hydroxyphenyl)-6-methoxyisoquinolin-1-one Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C=C1 XMQDHAVDMCJSCU-UHFFFAOYSA-N 0.000 claims description 2
• 206010002383 Angina Pectoris Diseases 0.000 claims description 2
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
• 208000006029 Cardiomegaly Diseases 0.000 claims description 2
• 206010038923 Retinopathy Diseases 0.000 claims description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
• 229940125876 compound 15a Drugs 0.000 claims description 2
• 230000000968 intestinal effect Effects 0.000 claims description 2
• 108010022197 lipoprotein cholesterol Proteins 0.000 claims 4
• 208000021046 prostate intraepithelial neoplasia Diseases 0.000 claims 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
• HIMXYYUQWXTNIB-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-6,8-dihydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1C=CN2C1=CC=C(O)C(F)=C1 HIMXYYUQWXTNIB-UHFFFAOYSA-N 0.000 claims 1
• AOIOAHVABNCLAJ-UHFFFAOYSA-N 4-(1,2-dibromoethyl)-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=C(O)C=C2C(C(Br)CBr)=C1 AOIOAHVABNCLAJ-UHFFFAOYSA-N 0.000 claims 1
• TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 claims 1
• BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 claims 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
• 206010016334 Feeling hot Diseases 0.000 claims 1
• 208000031481 Pathologic Constriction Diseases 0.000 claims 1
• 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 claims 1
• 206010039966 Senile dementia Diseases 0.000 claims 1
• NRIXVJQZYRQYPG-UHFFFAOYSA-N [4-chloro-6-methoxy-2-(4-methoxyphenyl)-1-oxoisoquinolin-8-yl] trifluoromethanesulfonate Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(OS(=O)(=O)C(F)(F)F)C=C(OC)C=C2C(Cl)=C1 NRIXVJQZYRQYPG-UHFFFAOYSA-N 0.000 claims 1
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
• 201000007094 prostatitis Diseases 0.000 claims 1
• TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 claims 1
• 230000035945 sensitivity Effects 0.000 claims 1
• 208000037804 stenosis Diseases 0.000 claims 1
• 230000036262 stenosis Effects 0.000 claims 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
• 229940088597 hormone Drugs 0.000 abstract description 10
• 239000005556 hormone Substances 0.000 abstract description 10
• 230000036542 oxidative stress Effects 0.000 abstract description 10
• 208000008589 Obesity Diseases 0.000 abstract description 7
• 235000020824 obesity Nutrition 0.000 abstract description 7
• 208000027866 inflammatory disease Diseases 0.000 abstract description 5
• 208000012902 Nervous system disease Diseases 0.000 abstract description 3
• 208000025966 Neurological disease Diseases 0.000 abstract description 2
• 239000000203 mixture Substances 0.000 description 141
• 210000004027 cell Anatomy 0.000 description 93
• 229940125388 beta agonist Drugs 0.000 description 89
• 238000005481 NMR spectroscopy Methods 0.000 description 77
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
• 238000000034 method Methods 0.000 description 57
• 239000000126 substance Substances 0.000 description 51
• 239000000243 solution Substances 0.000 description 49
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 48
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
• 210000004885 white matter Anatomy 0.000 description 48
• 239000007787 solid Substances 0.000 description 43
• 230000015572 biosynthetic process Effects 0.000 description 41
• 230000008018 melting Effects 0.000 description 41
• 238000002844 melting Methods 0.000 description 41
• 239000000262 estrogen Substances 0.000 description 39
• 229940011871 estrogen Drugs 0.000 description 38
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
• 238000003786 synthesis reaction Methods 0.000 description 35
• 230000002829 reductive effect Effects 0.000 description 33
• 238000006243 chemical reaction Methods 0.000 description 32
• 239000003446 ligand Substances 0.000 description 30
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 29
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
• 102000005962 receptors Human genes 0.000 description 28
• 108020003175 receptors Proteins 0.000 description 28
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 27
• 238000003756 stirring Methods 0.000 description 25
• 239000000741 silica gel Substances 0.000 description 23
• 229910002027 silica gel Inorganic materials 0.000 description 23
• 230000027455 binding Effects 0.000 description 22
• 229960005309 estradiol Drugs 0.000 description 22
• 102000015694 estrogen receptors Human genes 0.000 description 22
• 108010038795 estrogen receptors Proteins 0.000 description 22
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
• 238000003818 flash chromatography Methods 0.000 description 21
• 229930182833 estradiol Natural products 0.000 description 19
• 230000001965 increasing effect Effects 0.000 description 19
• 239000012299 nitrogen atmosphere Substances 0.000 description 19
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
• 238000010992 reflux Methods 0.000 description 18
• KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 17
• 239000000556 agonist Substances 0.000 description 17
• 230000035755 proliferation Effects 0.000 description 17
• 239000002904 solvent Substances 0.000 description 17
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 16
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 16
• 241000700159 Rattus Species 0.000 description 16
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 16
• 239000005557 antagonist Substances 0.000 description 16
• 238000011534 incubation Methods 0.000 description 16
• 230000002401 inhibitory effect Effects 0.000 description 16
• 230000005764 inhibitory process Effects 0.000 description 16
• 239000002609 medium Substances 0.000 description 16
• 108090000623 proteins and genes Proteins 0.000 description 16
• 239000003814 drug Substances 0.000 description 15
• 239000011541 reaction mixture Substances 0.000 description 15
• 229910052786 argon Inorganic materials 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 239000003642 reactive oxygen metabolite Substances 0.000 description 14
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
• USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 13
• 125000000623 heterocyclic group Chemical group 0.000 description 13
• 239000003921 oil Substances 0.000 description 13
• 235000019198 oils Nutrition 0.000 description 13
• 238000002360 preparation method Methods 0.000 description 13
• CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 13
• 108010010234 HDL Lipoproteins Proteins 0.000 description 12
• 102000015779 HDL Lipoproteins Human genes 0.000 description 12
• 230000014509 gene expression Effects 0.000 description 12
• 238000010791 quenching Methods 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 150000001412 amines Chemical class 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 102000004169 proteins and genes Human genes 0.000 description 11
• 230000009467 reduction Effects 0.000 description 11
• NQOZPTYIJQUKTJ-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)-4-oxo-6-(3-piperidin-1-ylpropoxy)quinazolin-3-yl]-n-propan-2-ylacetamide Chemical compound COC1=CC=CC(C=2N(C(=O)C3=CC(OCCCN4CCCCC4)=CC=C3N=2)CC(=O)NC(C)C)=C1 NQOZPTYIJQUKTJ-UHFFFAOYSA-N 0.000 description 10
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 10
• 230000003111 delayed effect Effects 0.000 description 10
• 230000001419 dependent effect Effects 0.000 description 10
• 239000000284 extract Substances 0.000 description 10
• 210000001508 eye Anatomy 0.000 description 10
• 201000001441 melanoma Diseases 0.000 description 10
• ZYCFMHCDZSVIGF-UHFFFAOYSA-N methyl 4-amino-1-(2-aminoethyl)-2-butylimidazo[4,5-c]quinoline-7-carboxylate Chemical compound NC1=NC=2C=C(C=CC=2C2=C1N=C(N2CCN)CCCC)C(=O)OC ZYCFMHCDZSVIGF-UHFFFAOYSA-N 0.000 description 10
• 239000012074 organic phase Substances 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• 235000018102 proteins Nutrition 0.000 description 10
• 239000011734 sodium Substances 0.000 description 10
• 230000004936 stimulating effect Effects 0.000 description 10
• 230000002792 vascular Effects 0.000 description 10
• 108010007622 LDL Lipoproteins Proteins 0.000 description 9
• 102000007330 LDL Lipoproteins Human genes 0.000 description 9
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 9
• 208000029725 Metabolic bone disease Diseases 0.000 description 9
• 239000003098 androgen Substances 0.000 description 9
• 230000003110 anti-inflammatory effect Effects 0.000 description 9
• 230000001028 anti-proliverative effect Effects 0.000 description 9
• 210000004204 blood vessel Anatomy 0.000 description 9
• 239000012267 brine Substances 0.000 description 9
• 230000004663 cell proliferation Effects 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 238000005160 1H NMR spectroscopy Methods 0.000 description 8
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 125000003342 alkenyl group Chemical group 0.000 description 8
• 230000003078 antioxidant effect Effects 0.000 description 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
• 230000005961 cardioprotection Effects 0.000 description 8
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
• 235000012000 cholesterol Nutrition 0.000 description 8
• 230000003247 decreasing effect Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 239000000839 emulsion Substances 0.000 description 8
• 210000001503 joint Anatomy 0.000 description 8
• 210000004185 liver Anatomy 0.000 description 8
• 230000009826 neoplastic cell growth Effects 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 230000001629 suppression Effects 0.000 description 8
• 229960001603 tamoxifen Drugs 0.000 description 8
• 229920000858 Cyclodextrin Polymers 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 7
• 206010049088 Osteopenia Diseases 0.000 description 7
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
• 210000000709 aorta Anatomy 0.000 description 7
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
• 210000003169 central nervous system Anatomy 0.000 description 7
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 7
• 231100000673 dose–response relationship Toxicity 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 230000009885 systemic effect Effects 0.000 description 7
• 210000004291 uterus Anatomy 0.000 description 7
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 6
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 6
• 206010061728 Bone lesion Diseases 0.000 description 6
• 208000002177 Cataract Diseases 0.000 description 6
• 238000008214 LDL Cholesterol Methods 0.000 description 6
• 208000002193 Pain Diseases 0.000 description 6
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• 230000003042 antagnostic effect Effects 0.000 description 6
• 239000003963 antioxidant agent Substances 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 238000013270 controlled release Methods 0.000 description 6
• 206010012601 diabetes mellitus Diseases 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 210000002889 endothelial cell Anatomy 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 238000001914 filtration Methods 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 201000002313 intestinal cancer Diseases 0.000 description 6
• 239000010410 layer Substances 0.000 description 6
• 230000003211 malignant effect Effects 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 235000010755 mineral Nutrition 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 230000036961 partial effect Effects 0.000 description 6
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 230000002062 proliferating effect Effects 0.000 description 6
• 230000001681 protective effect Effects 0.000 description 6
• 230000001850 reproductive effect Effects 0.000 description 6
• 230000002207 retinal effect Effects 0.000 description 6
• 208000011580 syndromic disease Diseases 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 6
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
• 208000020084 Bone disease Diseases 0.000 description 5
• 206010012689 Diabetic retinopathy Diseases 0.000 description 5
• 206010017076 Fracture Diseases 0.000 description 5
• 206010019708 Hepatic steatosis Diseases 0.000 description 5
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
• 206010030113 Oedema Diseases 0.000 description 5
• 208000024313 Testicular Neoplasms Diseases 0.000 description 5
• 208000002495 Uterine Neoplasms Diseases 0.000 description 5
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 235000006708 antioxidants Nutrition 0.000 description 5
• 210000001367 artery Anatomy 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 229910052791 calcium Inorganic materials 0.000 description 5
• 239000011575 calcium Substances 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 235000010418 carrageenan Nutrition 0.000 description 5
• 239000000679 carrageenan Substances 0.000 description 5
• 229920001525 carrageenan Polymers 0.000 description 5
• 229940113118 carrageenan Drugs 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 230000003930 cognitive ability Effects 0.000 description 5
• 208000026758 coronary atherosclerosis Diseases 0.000 description 5
• 239000008121 dextrose Substances 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 150000003840 hydrochlorides Chemical class 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 208000017169 kidney disease Diseases 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 239000011777 magnesium Substances 0.000 description 5
• 230000036651 mood Effects 0.000 description 5
• 230000003287 optical effect Effects 0.000 description 5
• 230000036407 pain Effects 0.000 description 5
• 239000004031 partial agonist Substances 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 229940049953 phenylacetate Drugs 0.000 description 5
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 229960004618 prednisone Drugs 0.000 description 5
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 5
• 229940044601 receptor agonist Drugs 0.000 description 5
• 239000000018 receptor agonist Substances 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 238000001308 synthesis method Methods 0.000 description 5
• 230000002194 synthesizing effect Effects 0.000 description 5
• 210000003932 urinary bladder Anatomy 0.000 description 5
• 206010046766 uterine cancer Diseases 0.000 description 5
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
• DDLJWWYULDUBGA-UHFFFAOYSA-N 6-methoxy-2h-isoquinolin-1-one Chemical compound OC1=NC=CC2=CC(OC)=CC=C21 DDLJWWYULDUBGA-UHFFFAOYSA-N 0.000 description 4
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 201000004569 Blindness Diseases 0.000 description 4
• 206010065687 Bone loss Diseases 0.000 description 4
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 206010020880 Hypertrophy Diseases 0.000 description 4
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 206010057644 Testis cancer Diseases 0.000 description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 230000001270 agonistic effect Effects 0.000 description 4
• 125000001931 aliphatic group Chemical group 0.000 description 4
• 150000003973 alkyl amines Chemical class 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 238000009167 androgen deprivation therapy Methods 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 229910052799 carbon Inorganic materials 0.000 description 4
• 231100000504 carcinogenesis Toxicity 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• 229940097362 cyclodextrins Drugs 0.000 description 4
• 230000008021 deposition Effects 0.000 description 4
• 125000005265 dialkylamine group Chemical group 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 239000003889 eye drop Substances 0.000 description 4
• 229940012356 eye drops Drugs 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 208000019622 heart disease Diseases 0.000 description 4
• 238000010438 heat treatment Methods 0.000 description 4
• 238000002657 hormone replacement therapy Methods 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 108020001756 ligand binding domains Proteins 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 239000012669 liquid formulation Substances 0.000 description 4
• 210000001853 liver microsome Anatomy 0.000 description 4
• 239000006210 lotion Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 230000027939 micturition Effects 0.000 description 4
• 238000013508 migration Methods 0.000 description 4
• 239000002480 mineral oil Substances 0.000 description 4
• 235000010446 mineral oil Nutrition 0.000 description 4
• 210000003470 mitochondria Anatomy 0.000 description 4
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 201000008482 osteoarthritis Diseases 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 150000002989 phenols Chemical class 0.000 description 4
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 235000013772 propylene glycol Nutrition 0.000 description 4
• 230000006950 reactive oxygen species formation Effects 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 239000008107 starch Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 229940032147 starch Drugs 0.000 description 4
• 125000001424 substituent group Chemical group 0.000 description 4
• 201000003120 testicular cancer Diseases 0.000 description 4
• 125000004001 thioalkyl group Chemical group 0.000 description 4
• 150000003573 thiols Chemical class 0.000 description 4
• 210000005167 vascular cell Anatomy 0.000 description 4
• VUKZWUYSEFVTRB-OSWZUBHSSA-N (4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-7,10,13-trimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound C([C@H]1CC2C)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 VUKZWUYSEFVTRB-OSWZUBHSSA-N 0.000 description 3
• SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 3
• PTHRFKANAKCVAH-UHFFFAOYSA-N 1-(2-piperidin-1-ylethoxy)isoquinolin-6-ol Chemical compound N=1C=CC2=CC(O)=CC=C2C=1OCCN1CCCCC1 PTHRFKANAKCVAH-UHFFFAOYSA-N 0.000 description 3
• PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 3
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
• UCDBLYHPJMMFMY-UHFFFAOYSA-N 8-bromoquinoline-4-carbonitrile Chemical class C1=CN=C2C(Br)=CC=CC2=C1C#N UCDBLYHPJMMFMY-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 208000005623 Carcinogenesis Diseases 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
• 206010015150 Erythema Diseases 0.000 description 3
• 229940102550 Estrogen receptor antagonist Drugs 0.000 description 3
• 239000001856 Ethyl cellulose Substances 0.000 description 3
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
• 208000004930 Fatty Liver Diseases 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 201000005569 Gout Diseases 0.000 description 3
• 229920002907 Guar gum Polymers 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
• 206010058359 Hypogonadism Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
• 206010033128 Ovarian cancer Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 208000000453 Skin Neoplasms Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 229920002125 Sokalan® Polymers 0.000 description 3
• 108010085012 Steroid Receptors Proteins 0.000 description 3
• 102000040945 Transcription factor Human genes 0.000 description 3
• 108091023040 Transcription factor Proteins 0.000 description 3
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
• 206010052428 Wound Diseases 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 208000038016 acute inflammation Diseases 0.000 description 3
• 230000006022 acute inflammation Effects 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 108010080146 androgen receptors Proteins 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 235000010323 ascorbic acid Nutrition 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 230000037182 bone density Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000036952 cancer formation Effects 0.000 description 3
• 229960001631 carbomer Drugs 0.000 description 3
• 210000000748 cardiovascular system Anatomy 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
• 229960000975 daunorubicin Drugs 0.000 description 3
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 238000010494 dissociation reaction Methods 0.000 description 3
• 230000005593 dissociations Effects 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 238000009164 estrogen replacement therapy Methods 0.000 description 3
• 235000019325 ethyl cellulose Nutrition 0.000 description 3
• 229920001249 ethyl cellulose Polymers 0.000 description 3
• 229960004667 ethyl cellulose Drugs 0.000 description 3
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
• 229940093471 ethyl oleate Drugs 0.000 description 3
• 208000010706 fatty liver disease Diseases 0.000 description 3
• 229940014259 gelatin Drugs 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 239000000665 guar gum Substances 0.000 description 3
• 235000010417 guar gum Nutrition 0.000 description 3
• 229960002154 guar gum Drugs 0.000 description 3
• 229940093915 gynecological organic acid Drugs 0.000 description 3
• 201000000079 gynecomastia Diseases 0.000 description 3
• 125000004464 hydroxyphenyl group Chemical group 0.000 description 3
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
• 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 238000001361 intraarterial administration Methods 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical group C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 210000005075 mammary gland Anatomy 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• UXNGIPQFEREBMG-UHFFFAOYSA-N methyl 4-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-8-carboxylate Chemical compound O=C1C=2C(C(=O)OC)=CC(O)=CC=2C(Br)=CN1C1=CC=C(O)C=C1 UXNGIPQFEREBMG-UHFFFAOYSA-N 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 210000003739 neck Anatomy 0.000 description 3
• 230000009871 nonspecific binding Effects 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 150000007524 organic acids Chemical class 0.000 description 3
• 235000005985 organic acids Nutrition 0.000 description 3
• 150000002895 organic esters Chemical class 0.000 description 3
• 230000003647 oxidation Effects 0.000 description 3
• 238000007254 oxidation reaction Methods 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 230000035935 pregnancy Effects 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 229960002429 proline Drugs 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 230000004224 protection Effects 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 150000003254 radicals Chemical class 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 230000008054 signal transmission Effects 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 210000002460 smooth muscle Anatomy 0.000 description 3
• 229940083542 sodium Drugs 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 235000015424 sodium Nutrition 0.000 description 3
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
• 239000011973 solid acid Substances 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 231100000240 steatosis hepatitis Toxicity 0.000 description 3
• 102000005969 steroid hormone receptors Human genes 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 150000003871 sulfonates Chemical class 0.000 description 3
• 210000001258 synovial membrane Anatomy 0.000 description 3
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
• 230000006442 vascular tone Effects 0.000 description 3
• 210000005166 vasculature Anatomy 0.000 description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
• VLSRUFWCGBMYDJ-ONEGZZNKSA-N (e)-3-(3,5-dimethoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(OC)=CC(\C=C\C(O)=O)=C1 VLSRUFWCGBMYDJ-ONEGZZNKSA-N 0.000 description 2
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• KQDRFFKUMBIKIF-UHFFFAOYSA-N 1,2-dihydroisoquinoline-4-carbonitrile Chemical compound C1=CC=C2C(C#N)=CNCC2=C1 KQDRFFKUMBIKIF-UHFFFAOYSA-N 0.000 description 2
• VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 2
• LZPNXAULYJPXEH-AATRIKPKSA-N 3-Methoxycinnamic acid Chemical compound COC1=CC=CC(\C=C\C(O)=O)=C1 LZPNXAULYJPXEH-AATRIKPKSA-N 0.000 description 2
• WZKNWOSGBYOMOR-UHFFFAOYSA-N 4-bromo-2-(4-fluorophenyl)-6-hydroxyisoquinolin-1-one Chemical compound C=1C(O)=CC=C(C2=O)C=1C(Br)=CN2C1=CC=C(F)C=C1 WZKNWOSGBYOMOR-UHFFFAOYSA-N 0.000 description 2
• UQJVSWJIGSWDBK-UHFFFAOYSA-N 6,8-dihydroxy-2-(4-hydroxyphenyl)-4-phenylisoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C=C2C(C=2C=CC=CC=2)=C1 UQJVSWJIGSWDBK-UHFFFAOYSA-N 0.000 description 2
• JAUASKQGRAVEBF-UHFFFAOYSA-N 6,8-dihydroxy-2-(4-hydroxyphenyl)-5-(trifluoromethylsulfonyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C(S(=O)(=O)C(F)(F)F)=C2C=C1 JAUASKQGRAVEBF-UHFFFAOYSA-N 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• GCJZYOIXXVVQKC-UHFFFAOYSA-N 6-hydroxy-2h-isoquinolin-1-one Chemical compound C1=CNC(=O)C=2C1=CC(O)=CC=2 GCJZYOIXXVVQKC-UHFFFAOYSA-N 0.000 description 2
• LRIYURUHCZKVOW-UHFFFAOYSA-N 6-methoxy-1-(2-piperidin-1-ylethoxy)isoquinoline Chemical compound N=1C=CC2=CC(OC)=CC=C2C=1OCCN1CCCCC1 LRIYURUHCZKVOW-UHFFFAOYSA-N 0.000 description 2
• QDBXREDOQFLXOU-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)-4-phenylisoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(OC)C=C2C(C=2C=CC=CC=2)=C1 QDBXREDOQFLXOU-UHFFFAOYSA-N 0.000 description 2
• XWGJIIQTSLZFQU-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CC=C(OC)C=C2C=C1 XWGJIIQTSLZFQU-UHFFFAOYSA-N 0.000 description 2
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
• 241000251468 Actinopterygii Species 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 102100032187 Androgen receptor Human genes 0.000 description 2
• 200000000007 Arterial disease Diseases 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• 208000006386 Bone Resorption Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006811 Bursitis Diseases 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 102000016938 Catalase Human genes 0.000 description 2
• 108010053835 Catalase Proteins 0.000 description 2
• 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 206010012289 Dementia Diseases 0.000 description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
• 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 2
• 108010007005 Estrogen Receptor alpha Proteins 0.000 description 2
• 108010041356 Estrogen Receptor beta Proteins 0.000 description 2
• 102100038595 Estrogen receptor Human genes 0.000 description 2
• 229940122880 Estrogen receptor agonist Drugs 0.000 description 2
• 102100029951 Estrogen receptor beta Human genes 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 208000001640 Fibromyalgia Diseases 0.000 description 2
• 108090000331 Firefly luciferases Proteins 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
• RNPABQVCNAUEIY-GUQYYFCISA-N Germine Chemical compound O1[C@@]([C@H](CC[C@]23C)O)(O)[C@H]3C[C@@H](O)[C@@H]([C@]3(O)[C@@H](O)[C@H](O)[C@@H]4[C@]5(C)O)[C@@]12C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 RNPABQVCNAUEIY-GUQYYFCISA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 206010020675 Hypermetropia Diseases 0.000 description 2
• 208000006001 Hypothalamic Neoplasms Diseases 0.000 description 2
• 208000004575 Infectious Arthritis Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 229930182821 L-proline Natural products 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 206010067125 Liver injury Diseases 0.000 description 2
• 102000009151 Luteinizing Hormone Human genes 0.000 description 2
• 108010073521 Luteinizing Hormone Proteins 0.000 description 2
• 208000016604 Lyme disease Diseases 0.000 description 2
• 208000031471 Macular fibrosis Diseases 0.000 description 2
• 208000002720 Malnutrition Diseases 0.000 description 2
• 208000001826 Marfan syndrome Diseases 0.000 description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 description 2
• 229910017976 MgO 4 Inorganic materials 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 2
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• 201000002481 Myositis Diseases 0.000 description 2
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 244000061176 Nicotiana tabacum Species 0.000 description 2
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 108090000445 Parathyroid hormone Proteins 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010039705 Scleritis Diseases 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• 208000004350 Strabismus Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 235000019486 Sunflower oil Nutrition 0.000 description 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
• 208000000491 Tendinopathy Diseases 0.000 description 2
• 206010043255 Tendonitis Diseases 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 206010046543 Urinary incontinence Diseases 0.000 description 2
• 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000035508 accumulation Effects 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 235000011054 acetic acid Nutrition 0.000 description 2
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
• 239000012491 analyte Substances 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 210000003433 aortic smooth muscle cell Anatomy 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 230000002917 arthritic effect Effects 0.000 description 2
• 210000001188 articular cartilage Anatomy 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 230000003143 atherosclerotic effect Effects 0.000 description 2
• 201000004988 autoimmune vasculitis Diseases 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 230000008468 bone growth Effects 0.000 description 2
• 230000010478 bone regeneration Effects 0.000 description 2
• 230000024279 bone resorption Effects 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 210000003855 cell nucleus Anatomy 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 208000002849 chondrocalcinosis Diseases 0.000 description 2
• 210000003161 choroid Anatomy 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 235000015165 citric acid Nutrition 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 230000009137 competitive binding Effects 0.000 description 2
• 229940126543 compound 14 Drugs 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 208000018631 connective tissue disease Diseases 0.000 description 2
• 206010011005 corneal dystrophy Diseases 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 210000000172 cytosol Anatomy 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 description 2
• FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 229940048820 edetates Drugs 0.000 description 2
• 229920001971 elastomer Polymers 0.000 description 2
• 239000003792 electrolyte Substances 0.000 description 2
• 230000001804 emulsifying effect Effects 0.000 description 2
• 210000000750 endocrine system Anatomy 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 230000001076 estrogenic effect Effects 0.000 description 2
• 230000003090 exacerbative effect Effects 0.000 description 2
• 208000024519 eye neoplasm Diseases 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 235000019688 fish Nutrition 0.000 description 2
• 238000001917 fluorescence detection Methods 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• RNPABQVCNAUEIY-UHFFFAOYSA-N germine Natural products O1C(C(CCC23C)O)(O)C3CC(O)C(C3(O)C(O)C(O)C4C5(C)O)C12CC3C4CN1C5CCC(C)C1 RNPABQVCNAUEIY-UHFFFAOYSA-N 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 201000010536 head and neck cancer Diseases 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 231100000234 hepatic damage Toxicity 0.000 description 2
• 230000003054 hormonal effect Effects 0.000 description 2
• 235000011167 hydrochloric acid Nutrition 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 201000006318 hyperopia Diseases 0.000 description 2
• 230000004305 hyperopia Effects 0.000 description 2
• 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
• 208000000509 infertility Diseases 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• 231100000535 infertility Toxicity 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 208000020082 intraepithelial neoplasia Diseases 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 230000002262 irrigation Effects 0.000 description 2
• 238000003973 irrigation Methods 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 208000018937 joint inflammation Diseases 0.000 description 2
• 206010023332 keratitis Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 229960001375 lactose Drugs 0.000 description 2
• 229920006008 lipopolysaccharide Polymers 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 230000008818 liver damage Effects 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 229940040129 luteinizing hormone Drugs 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 230000001071 malnutrition Effects 0.000 description 2
• 235000000824 malnutrition Nutrition 0.000 description 2
• 238000002483 medication Methods 0.000 description 2
• 210000002752 melanocyte Anatomy 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000003020 moisturizing effect Effects 0.000 description 2
• 210000001721 multinucleated osteoclast Anatomy 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
• 230000000324 neuroprotective effect Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 229960002748 norepinephrine Drugs 0.000 description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
• 238000011580 nude mouse model Methods 0.000 description 2
• 208000015380 nutritional deficiency disease Diseases 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 208000001749 optic atrophy Diseases 0.000 description 2
• 208000020911 optic nerve disease Diseases 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 239000003208 petroleum Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• 229960001802 phenylephrine Drugs 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 235000011007 phosphoric acid Nutrition 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 210000004180 plasmocyte Anatomy 0.000 description 2
• 229920001983 poloxamer Polymers 0.000 description 2
• 229920001987 poloxamine Polymers 0.000 description 2
• 235000013824 polyphenols Nutrition 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 229960004919 procaine Drugs 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 230000004850 protein–protein interaction Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 230000011514 reflex Effects 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
• 210000001525 retina Anatomy 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 239000012047 saturated solution Substances 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 201000001223 septic arthritis Diseases 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 230000000391 smoking effect Effects 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 239000003549 soybean oil Substances 0.000 description 2
• 235000012424 soybean oil Nutrition 0.000 description 2
• 239000008174 sterile solution Substances 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 230000003637 steroidlike Effects 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
• 239000002600 sunflower oil Substances 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 230000002889 sympathetic effect Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 201000004415 tendinitis Diseases 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 229930192474 thiophene Natural products 0.000 description 2
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
• 201000002510 thyroid cancer Diseases 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000035903 transrepression Effects 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 150000003626 triacylglycerols Chemical class 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 210000000689 upper leg Anatomy 0.000 description 2
• 210000003708 urethra Anatomy 0.000 description 2
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
• 230000024883 vasodilation Effects 0.000 description 2
• 235000013311 vegetables Nutrition 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
• HPZPEKLFKWMPJM-ONEGZZNKSA-N (e)-3-(3,5-dimethoxyphenyl)prop-2-enoyl chloride Chemical compound COC1=CC(OC)=CC(\C=C\C(Cl)=O)=C1 HPZPEKLFKWMPJM-ONEGZZNKSA-N 0.000 description 1
• KFHHPVVJLXPHJL-UPHRSURJSA-N (z)-4-hydroperoxy-4-oxobut-2-enoic acid Chemical class OOC(=O)\C=C/C(O)=O KFHHPVVJLXPHJL-UPHRSURJSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical class CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• SCWPNMHQRGNQHH-AATRIKPKSA-N 2-[(e)-2-carboxyethenyl]benzoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1C(O)=O SCWPNMHQRGNQHH-AATRIKPKSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• JDDAFHUEOVUDFJ-UHFFFAOYSA-N 2-iodobenzonitrile Chemical compound IC1=CC=CC=C1C#N JDDAFHUEOVUDFJ-UHFFFAOYSA-N 0.000 description 1
• JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
• 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
• MNUOZFHYBCRUOD-UHFFFAOYSA-N 3-hydroxyphthalic acid Chemical class OC(=O)C1=CC=CC(O)=C1C(O)=O MNUOZFHYBCRUOD-UHFFFAOYSA-N 0.000 description 1
• IZDIUTIBXPSGOA-UHFFFAOYSA-N 4,5-dihydroxy-1,2-dihydropyrazol-3-one Chemical compound OC1=NNC(O)=C1O IZDIUTIBXPSGOA-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
• NGNFBVGQCAVUCR-UHFFFAOYSA-N 4-bromo-6-hydroxy-2-(4-hydroxy-3-methylphenyl)isoquinolin-1-one Chemical compound C1=C(O)C(C)=CC(N2C(C3=CC=C(O)C=C3C(Br)=C2)=O)=C1 NGNFBVGQCAVUCR-UHFFFAOYSA-N 0.000 description 1
• PHJMFHYDJCTEFA-UHFFFAOYSA-N 4-ethenyl-6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C=C2C(C=C)=C1 PHJMFHYDJCTEFA-UHFFFAOYSA-N 0.000 description 1
• VZSCCCSZIQBCNZ-UHFFFAOYSA-N 6,8-dihydroxy-2-(4-hydroxyphenyl)-1-oxoisoquinoline-4-carbonitrile Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C=C2C(C#N)=C1 VZSCCCSZIQBCNZ-UHFFFAOYSA-N 0.000 description 1
• KGZZMTWCVOBJOB-UHFFFAOYSA-N 6,8-dihydroxy-2-(4-hydroxyphenyl)-4-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1C(C1=CC(O)=CC(O)=C1C1=O)=CN1C1=CC=C(O)C=C1 KGZZMTWCVOBJOB-UHFFFAOYSA-N 0.000 description 1
• ZBJJSYPHZUNOND-UHFFFAOYSA-N 6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=C(O)C=C(O)C=C2C=C1 ZBJJSYPHZUNOND-UHFFFAOYSA-N 0.000 description 1
• XCJFEJPHCGHRTO-UHFFFAOYSA-N 6,8-dihydroxy-2-(4-hydroxyphenyl)isoquinoline-1-thione Chemical compound C1=CC(O)=CC=C1N1C(=S)C2=C(O)C=C(O)C=C2C=C1 XCJFEJPHCGHRTO-UHFFFAOYSA-N 0.000 description 1
• UJOQYPUDGCNYSS-UHFFFAOYSA-N 6,8-dihydroxy-2h-isoquinolin-1-one Chemical class C1=CNC(=O)C=2C1=CC(O)=CC=2O UJOQYPUDGCNYSS-UHFFFAOYSA-N 0.000 description 1
• FJORJVIJWZXBPD-UHFFFAOYSA-N 6,8-dimethoxy-2-(4-methoxyphenyl)isoquinolin-1-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(OC)C=C(OC)C=C2C=C1 FJORJVIJWZXBPD-UHFFFAOYSA-N 0.000 description 1
• RQNPAAMHEZHSNU-UHFFFAOYSA-N 6,8-dimethoxy-2h-isoquinolin-1-one Chemical compound OC1=NC=CC2=CC(OC)=CC(OC)=C21 RQNPAAMHEZHSNU-UHFFFAOYSA-N 0.000 description 1
• FATGBXBWZTXROD-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)-1h-isoquinoline-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C=C(C#N)C2=CC(OC)=CC=C2C1 FATGBXBWZTXROD-UHFFFAOYSA-N 0.000 description 1
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 206010001557 Albinism Diseases 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
• WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
• 201000009487 Amblyopia Diseases 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• 235000011437 Amygdalus communis Nutrition 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 208000009786 Anophthalmos Diseases 0.000 description 1
• 208000000103 Anorexia Nervosa Diseases 0.000 description 1
• 206010059199 Anterior chamber cleavage syndrome Diseases 0.000 description 1
• 206010002945 Aphakia Diseases 0.000 description 1
• 108010083590 Apoproteins Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000036487 Arthropathies Diseases 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 206010060971 Astrocytoma malignant Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 101710117545 C protein Proteins 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 208000018152 Cerebral disease Diseases 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 241001608562 Chalazion Species 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 208000033825 Chorioretinal atrophy Diseases 0.000 description 1
• 208000033379 Chorioretinopathy Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 108010004103 Chylomicrons Proteins 0.000 description 1
• 201000003101 Coloboma Diseases 0.000 description 1
• 208000036693 Color-vision disease Diseases 0.000 description 1
• 206010010214 Compression fracture Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 208000006069 Corneal Opacity Diseases 0.000 description 1
• 206010010996 Corneal degeneration Diseases 0.000 description 1
• 206010011013 Corneal erosion Diseases 0.000 description 1
• 206010011033 Corneal oedema Diseases 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 206010011971 Decreased interest Diseases 0.000 description 1
• 108020005199 Dehydrogenases Proteins 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 206010062356 Diabetic bullosis Diseases 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
• 208000003164 Diplopia Diseases 0.000 description 1
• 201000010374 Down Syndrome Diseases 0.000 description 1
• 201000000913 Duane retraction syndrome Diseases 0.000 description 1
• 208000005171 Dysmenorrhea Diseases 0.000 description 1
• 206010013935 Dysmenorrhoea Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 206010061842 Entropion Diseases 0.000 description 1
• 102100023688 Eotaxin Human genes 0.000 description 1
• 101710139422 Eotaxin Proteins 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• 241000289659 Erinaceidae Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 208000001692 Esotropia Diseases 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 201000005538 Exotropia Diseases 0.000 description 1
• 239000001116 FEMA 4028 Substances 0.000 description 1
• VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical class F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
• 208000003492 Fundus albipunctatus Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 102000001267 GSK3 Human genes 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 239000001828 Gelatine Substances 0.000 description 1
• 208000000527 Germinoma Diseases 0.000 description 1
• 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
• 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000007698 Gyrate Atrophy Diseases 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 108090000031 Hedgehog Proteins Proteins 0.000 description 1
• 102000003693 Hedgehog Proteins Human genes 0.000 description 1
• 206010019452 Hemianopia Diseases 0.000 description 1
• 208000007460 Hemianopsia Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 206010020100 Hip fracture Diseases 0.000 description 1
• 206010020112 Hirsutism Diseases 0.000 description 1
• 240000005979 Hordeum vulgare Species 0.000 description 1
• 235000007340 Hordeum vulgare Nutrition 0.000 description 1
• 208000016495 Horner Syndrome Diseases 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010020710 Hyperphagia Diseases 0.000 description 1
• 201000001431 Hyperuricemia Diseases 0.000 description 1
• 208000031354 Hyphema Diseases 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 108010046315 IDL Lipoproteins Proteins 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 108010004250 Inhibins Proteins 0.000 description 1
• 102000002746 Inhibins Human genes 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• 206010023232 Joint swelling Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
• 201000002287 Keratoconus Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 150000000994 L-ascorbates Chemical class 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• 108010028554 LDL Cholesterol Proteins 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 208000009795 Microphthalmos Diseases 0.000 description 1
• 108020005196 Mitochondrial DNA Proteins 0.000 description 1
• 206010027940 Mood altered Diseases 0.000 description 1
• 208000019022 Mood disease Diseases 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 229920001007 Nylon 4 Polymers 0.000 description 1
• ICJAOLALTGGCFE-UHFFFAOYSA-N OC=1N(C(C2=CC=CC=C2C=1)=O)C1=CC=C(C=C1)O Chemical compound OC=1N(C(C2=CC=CC=C2C=1)=O)C1=CC=C(C=C1)O ICJAOLALTGGCFE-UHFFFAOYSA-N 0.000 description 1
• 208000014723 Oculomotor Nerve disease Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 206010030247 Oestrogen deficiency Diseases 0.000 description 1
• 206010067572 Oestrogenic effect Diseases 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
• 206010061323 Optic neuropathy Diseases 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 102000004067 Osteocalcin Human genes 0.000 description 1
• 108090000573 Osteocalcin Proteins 0.000 description 1
• 102000009890 Osteonectin Human genes 0.000 description 1
• 108010077077 Osteonectin Proteins 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033712 Papilloedema Diseases 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 201000000016 Peters anomaly Diseases 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 201000007552 Pituitary carcinoma Diseases 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920000037 Polyproline Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 201000002154 Pterygium Diseases 0.000 description 1
• 206010037538 Pupils unequal Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
• 208000036891 RDH5-related retinopathy Diseases 0.000 description 1
• 208000036903 RLBP1-related retinopathy Diseases 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 206010038743 Restlessness Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 208000032430 Retinal dystrophy Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• 241000220317 Rosa Species 0.000 description 1
• 108091006165 SLC13 Proteins 0.000 description 1
• 102100037599 SPARC Human genes 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 206010039729 Scotoma Diseases 0.000 description 1
• 206010039984 Senile osteoporosis Diseases 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 206010040799 Skin atrophy Diseases 0.000 description 1
• 206010040844 Skin exfoliation Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
• 240000006394 Sorghum bicolor Species 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical class OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
• 208000001435 Thromboembolism Diseases 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000025609 Urogenital disease Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 108010069201 VLDL Cholesterol Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010047571 Visual impairment Diseases 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 206010048215 Xanthomatosis Diseases 0.000 description 1
• 241000212749 Zesius chrysomallus Species 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• VYEYJCBEXFTGBN-UHFFFAOYSA-N acetic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 VYEYJCBEXFTGBN-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 229940023476 agar Drugs 0.000 description 1
• 230000007172 age related pathology Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229920000615 alginic acid Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• 235000020224 almond Nutrition 0.000 description 1
• HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
• 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• ZOZLFBZFMZKVFW-UHFFFAOYSA-N aluminum;zinc Chemical compound [Al+3].[Zn+2] ZOZLFBZFMZKVFW-UHFFFAOYSA-N 0.000 description 1
• 206010001902 amaurosis Diseases 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 201000007696 anal canal cancer Diseases 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 102000001307 androgen receptors Human genes 0.000 description 1
• 238000009165 androgen replacement therapy Methods 0.000 description 1
• 206010068168 androgenetic alopecia Diseases 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 208000008303 aniridia Diseases 0.000 description 1
• 208000001239 anisocoria Diseases 0.000 description 1
• 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
• 201000004612 anterior uveitis Diseases 0.000 description 1
• RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
• 230000003712 anti-aging effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000002924 anti-infective effect Effects 0.000 description 1
• 230000002421 anti-septic effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• 239000002221 antipyretic Substances 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 230000004219 arterial function Effects 0.000 description 1
• 125000005228 aryl sulfonate group Chemical group 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 208000003464 asthenopia Diseases 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 201000009310 astigmatism Diseases 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 150000001555 benzenes Chemical class 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 206010005159 blepharospasm Diseases 0.000 description 1
• 230000000744 blepharospasm Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 229940112869 bone morphogenetic protein Drugs 0.000 description 1
• 230000010072 bone remodeling Effects 0.000 description 1
• 230000037118 bone strength Effects 0.000 description 1
• 150000001642 boronic acid derivatives Chemical class 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 150000001649 bromium compounds Chemical class 0.000 description 1
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical class BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
• 210000005252 bulbus oculi Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
• 229910052792 caesium Inorganic materials 0.000 description 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000003293 cardioprotective effect Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
• 208000030239 cerebral astrocytoma Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 239000012627 chemopreventive agent Substances 0.000 description 1
• 229940124443 chemopreventive agent Drugs 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 102000006533 chordin Human genes 0.000 description 1
• 108010008846 chordin Proteins 0.000 description 1
• 201000004709 chorioretinitis Diseases 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical class OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 210000003029 clitoris Anatomy 0.000 description 1
• GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
• 229960003608 clomifene Drugs 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 230000004456 color vision Effects 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 208000012839 conversion disease Diseases 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 208000021921 corneal disease Diseases 0.000 description 1
• 201000004778 corneal edema Diseases 0.000 description 1
• 201000004180 corneal endothelial dystrophy Diseases 0.000 description 1
• 201000007717 corneal ulcer Diseases 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960000913 crospovidone Drugs 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• JWOSTXBESVWMJW-UHFFFAOYSA-N cyclohexyl sulfamate Chemical class NS(=O)(=O)OC1CCCCC1 JWOSTXBESVWMJW-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 108091007930 cytoplasmic receptors Proteins 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 125000005534 decanoate group Chemical class 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000000779 depleting effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 235000015872 dietary supplement Nutrition 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 150000004656 dimethylamines Chemical class 0.000 description 1
• SHPKCSFVQGSAJU-UAIGNFCESA-L dipotassium;(z)-but-2-enedioate Chemical class [K+].[K+].[O-]C(=O)\C=C/C([O-])=O SHPKCSFVQGSAJU-UAIGNFCESA-L 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 235000005686 eating Nutrition 0.000 description 1
• 201000003079 ectropion Diseases 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 230000000678 effect on lipid Effects 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 230000001856 erectile effect Effects 0.000 description 1
• 210000005225 erectile tissue Anatomy 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 108020004067 estrogen-related receptors Proteins 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• 150000002169 ethanolamines Chemical class 0.000 description 1
• 150000002171 ethylene diamines Chemical class 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000004299 exfoliation Methods 0.000 description 1
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 235000019233 fast yellow AB Nutrition 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• 102000013361 fetuin Human genes 0.000 description 1
• 108060002885 fetuin Proteins 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 230000003480 fibrinolytic effect Effects 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229940084434 fungoid Drugs 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
• 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 229960003627 gemfibrozil Drugs 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 229940045109 genistein Drugs 0.000 description 1
• 235000006539 genistein Nutrition 0.000 description 1
• TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
• ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
• 201000003115 germ cell cancer Diseases 0.000 description 1
• 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 150000002315 glycerophosphates Chemical class 0.000 description 1
• 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 239000003163 gonadal steroid hormone Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 231100001261 hazardous Toxicity 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000005986 heart dysfunction Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 238000005734 heterodimerization reaction Methods 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• JRFKIOFLCXKVOT-UHFFFAOYSA-N hydroxymethylnicotinamide Chemical compound OCNC(=O)C1=CC=CN=C1 JRFKIOFLCXKVOT-UHFFFAOYSA-N 0.000 description 1
• 229950005422 hydroxymethylnicotinamide Drugs 0.000 description 1
• 201000010930 hyperostosis Diseases 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 230000000642 iatrogenic effect Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 229940124622 immune-modulator drug Drugs 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000000893 inhibin Substances 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
• 150000004694 iodide salts Chemical class 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 201000004614 iritis Diseases 0.000 description 1
• JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
• 208000023589 ischemic disease Diseases 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• GPVPDRHTRGTSIH-UHFFFAOYSA-N isoquinolin-6-ol Chemical compound C1=NC=CC2=CC(O)=CC=C21 GPVPDRHTRGTSIH-UHFFFAOYSA-N 0.000 description 1
• PZNNHPZBZRHNDO-UHFFFAOYSA-N isoquinoline-8-carbonitrile Chemical compound C1=NC=C2C(C#N)=CC=CC2=C1 PZNNHPZBZRHNDO-UHFFFAOYSA-N 0.000 description 1
• 150000002537 isoquinolines Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 235000015110 jellies Nutrition 0.000 description 1
• 239000008274 jelly Substances 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
• 229960001021 lactose monohydrate Drugs 0.000 description 1
• 208000030175 lameness Diseases 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 230000006372 lipid accumulation Effects 0.000 description 1
• 230000004132 lipogenesis Effects 0.000 description 1
• 150000002634 lipophilic molecules Chemical class 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 229940063720 lopid Drugs 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• 150000004701 malic acid derivatives Chemical class 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 230000015654 memory Effects 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 208000011661 metabolic syndrome X Diseases 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 238000006140 methanolysis reaction Methods 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical class CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• 150000003956 methylamines Chemical class 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 230000004089 microcirculation Effects 0.000 description 1
• 201000010478 microphthalmia Diseases 0.000 description 1
• 239000007758 minimum essential medium Substances 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 230000007510 mood change Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 238000000465 moulding Methods 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 230000001114 myogenic effect Effects 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• 229950002366 nafoxidine Drugs 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 210000001020 neural plate Anatomy 0.000 description 1
• 210000005157 neural retina Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 150000005480 nicotinamides Chemical class 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 206010029864 nystagmus Diseases 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000005474 octanoate group Chemical class 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 206010030875 ophthalmoplegia Diseases 0.000 description 1
• 210000001328 optic nerve Anatomy 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical class N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 230000001009 osteoporotic effect Effects 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 235000020830 overeating Nutrition 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 230000010627 oxidative phosphorylation Effects 0.000 description 1
• 150000002927 oxygen compounds Chemical class 0.000 description 1
• 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 210000003695 paranasal sinus Anatomy 0.000 description 1
• 210000002990 parathyroid gland Anatomy 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000008010 parenteral excipient Substances 0.000 description 1
• 230000003950 pathogenic mechanism Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 230000036581 peripheral resistance Effects 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 150000001564 phenyl benzoates Chemical class 0.000 description 1
• DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 125000005498 phthalate group Chemical class 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000003075 phytoestrogen Substances 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 150000004885 piperazines Chemical class 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 208000011866 pituitary adenocarcinoma Diseases 0.000 description 1
• 201000002511 pituitary cancer Diseases 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 125000005547 pivalate group Chemical group 0.000 description 1
• 230000007505 plaque formation Effects 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 150000008442 polyphenolic compounds Chemical class 0.000 description 1
• 108010026466 polyproline Proteins 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 230000036316 preload Effects 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 102000003998 progesterone receptors Human genes 0.000 description 1
• 108090000468 progesterone receptors Proteins 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 210000001747 pupil Anatomy 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 150000003222 pyridines Chemical class 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 230000030541 receptor transactivation Effects 0.000 description 1
• 238000002278 reconstructive surgery Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 238000000611 regression analysis Methods 0.000 description 1
• 230000035806 respiratory chain Effects 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 230000003938 response to stress Effects 0.000 description 1
• 210000001927 retinal artery Anatomy 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 208000004644 retinal vein occlusion Diseases 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 238000007157 ring contraction reaction Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 201000008525 senile cataract Diseases 0.000 description 1
• 230000035946 sexual desire Effects 0.000 description 1
• 201000006476 shipyard eye Diseases 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 208000022925 sleep disturbance Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940023144 sodium glycolate Drugs 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000012265 solid product Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 230000000365 steroidogenetic effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 229960004793 sucrose Drugs 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 201000003826 superficial keratitis Diseases 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 206010042772 syncope Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 229920002994 synthetic fiber Polymers 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 150000003942 tert-butylamines Chemical class 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 150000003567 thiocyanates Chemical class 0.000 description 1
• 208000014648 third cranial nerve disease Diseases 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 208000008732 thymoma Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• 125000005490 tosylate group Chemical group 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 206010044325 trachoma Diseases 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 239000001069 triethyl citrate Substances 0.000 description 1
• VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
• 235000013769 triethyl citrate Nutrition 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
• DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 230000001573 trophoblastic effect Effects 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 201000002327 urinary tract obstruction Diseases 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 238000003828 vacuum filtration Methods 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 239000002966 varnish Substances 0.000 description 1
• 231100000216 vascular lesion Toxicity 0.000 description 1
• 230000004865 vascular response Effects 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 230000004304 visual acuity Effects 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• 210000004127 vitreous body Anatomy 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 239000012224 working solution Substances 0.000 description 1
• 210000000707 wrist Anatomy 0.000 description 1